** Brokerage H.C. Wainwright starts coverage of drug developer Palvella Therapeutics PVLA.O with "buy" rating and PT of $38 - a 3x upside to Tuesday's close
** Co is testing a topical form of rapamycin called Qtorin in late-stage studies to treat two rare and chronic skin diseases called microcystic lymphatic malformations and cutaneous venous malformations
** There is a high unmet need because no approved therapies exist for these conditions - H.C. Wainwright
** Brokerage says Palvella's formulation addresses critical limitations of other forms of the drug, such as poor skin penetration, systemic toxicity, and chemical instability
** Says doctors have expressed optimism about the potential for a topical rapamycin therapy, as current treatments such as lasers, surgery or off-label medicines are either ineffective or only provide temporary relief
** Late-stage data from one of the trials is expected in early 2026 and brokerage says the drug could be launched by 2027
** Also expects sales of Qtorin rapamycin to grow to $381 million by 2034
** As of last close, stock down ~19% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.